Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia

Archives of General Psychiatry

Volumn 69, Issue 5, 2012, Pages 476-483

  Tiihonena, Jari ^a,b,f,g   Suokas, Jaana T ^f,h   Suvisaari, Jaana M ^e,f   Haukka, Jari ^c,e   Korhonen, Pasi ^c,d  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c EPID Research Oy   (Finland)

^d Stat Finn Oy   (Finland)

^e TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^f NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^g KAROLINSKA INSTITUTE   (Sweden)

^h UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

1,1 DICHLORO 2,2 BIS(4 CHLOROPHENYL)ETHANE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CHLORDIAZEPOXIDE; CLONAZEPAM; DIAZEPAM; MIDAZOLAM MALEATE; NEUROLEPTIC AGENT; NITRAZEPAM; NO3AE01; OLANZAPINE; OXAZEPAM; TEMAZEPAM; UNCLASSIFIED DRUG; ZALEPLON; ZOLPIDEM TARTRATE; ZOPICLONE;

ADOLESCENT; ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; EPILEPSY; FEMALE; FINLAND; GEOGRAPHY; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MONOTHERAPY; MORTALITY; OUTPATIENT CARE; POLYPHARMACY; PRESCRIPTION; REGISTER; SCHIZOPHRENIA; SOCIAL STATUS; SUICIDE; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; FINLAND; HUMANS; MALE; MIDDLE AGED; POLYPHARMACY; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84860761426     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2011.1532     Document Type: Article

References (34)

1. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: ameta-analysis of randomized controlled trials. Schizophr Bull. 2009;35(2):443-457.
2. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W; Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71-93.
3. Volz A, Khorsand V, Gillies D, Leucht S. Benzodiazepines for schizophrenia. Cochrane Database Syst Rev. 2007; (1): CD006391.
4. Rummel C, Kissling W, Leucht S. Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials. Schizophr Res. 2005;80(1):85-97. (Pubitemid 41587466)
5. Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J. 11-year follow-up of mortality in patients with schizophrenia: a populationbased cohort study (FIN11 study). Lancet. 2009;374(9690):620-627.
6. Baandrup L, Gasse C, Jensen VD, Glenthoj BY, Nordentoft M, Lublin H, Fink-Jensen A, Lindhardt A, Mortensen PB. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry. 2010;71(2):103-108.
7. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603-609.
8. Tiihonen J, Wahlbeck K, Lönnqvist J, Klaukka T, Ioannidis JPA, Volavka J, Haukka J. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ. 2006;333(7561):224-227. (Pubitemid 44406713)
9. Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Tanskanen A, Haukka J. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry. 2006;63(12):1358-1367. (Pubitemid 44878519)
10. Suvisaari JM, Haukka JK, Tanskanen AJ, Lönnqvist JK. Decline in the incidence of schizophrenia in Finnish cohorts born from 1954 to 1965. Arch Gen Psychiatry. 1999;56(8):733-740. (Pubitemid 29357735)
11. Isohanni M, Mäkikyrö T, Moring J, Räsänen P, Hakko H, Partanen U, Koiranen M, Jones P. A comparison of clinical and research DSM-III-R diagnoses of schizophrenia in a Finnish national birth cohort: clinical and research diagnoses of schizophrenia. Soc Psychiatry Psychiatr Epidemiol. 1997;32(5):303-308. (Pubitemid 27336339)
12. Cannon TD, Kaprio J, Lönnqvist J, Huttunen M, Koskenvuo M. The genetic epidemiology of schizophrenia in a Finnish twin cohort: a population-based modeling study. Arch Gen Psychiatry. 1998;55(1):67-74. (Pubitemid 28069041)
13. Mäkikyrö T, Isohanni M, Moring J, Hakko H, Hovatta I, Lönnqvist J. Accuracy of register-based schizophrenia diagnoses in a genetic study. Eur Psychiatry. 1998;13(2):57-62. (Pubitemid 28215849)
14. World Health Organization. ATC/DDD index 2012. http://www.whocc.no/atc- ddd-index/. Accessed February 4, 2012.
15. Mantel-Teeuwisse AK, Klungel OH, Verschuren WM, Porsius A, de Boer A. Comparison of different methods to estimate prevalence of drug use by using pharmacy records. J Clin Epidemiol. 2001;54(11):1181-1186. (Pubitemid 33033249)
16. Nielsen LH, Løkkegaard E, Andreasen AH, Keiding N. Using prescription registries to define continuous drug use: how to fill gaps between prescriptions. Pharmacoepidemiol Drug Saf. 2008;17(4):384-388. (Pubitemid 351566355)
17. Johansson LA, Korpi H, Pedersen AG. NOMESCO Report on Mortality Statistics for the Nordic/Baltic Countries. Copenhagen, Denmark: NOMESCO; 2010. Product 92.
18. Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11(5):561-570. (Pubitemid 30660035)
19. Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia: antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry. 1998;173:325-329. (Pubitemid 28454819)
20. Joukamaa M, Heliövaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry. 2006;188:122-127. (Pubitemid 43171066)
21. Ioannidis JP, Haidich AB, Pappa M, Pantazis N, Kokori SI, Tektonidou MG, Contopoulos-Ioannidis DG, Lau J. Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA. 2001;286(7):821-830. (Pubitemid 33015576)
22. Glick ID, Pham D, Davis JM. Concomitant medications may not improve outcome of antipsychotic monotherapy for stabilized patients with nonacute schizophrenia. J Clin Psychiatry. 2006;67(8):1261-1265. (Pubitemid 44439699)
23. Heilä H, Isometsä ET, Henriksson MM, Heikkinen ME, Marttunen MJ, Lönnqvist JK. Suicide and schizophrenia: a nationwide psychological autopsy study on ageand sex-specific clinical characteristics of 92 suicide victims with schizophrenia. Am J Psychiatry. 1997;154(9):1235-1242. (Pubitemid 27369174)
24. Linnér L, Wiker C, Wadenberg ML, Schalling M, Svensson TH. Noradrenaline reuptake inhibition enhances the antipsychotic-like effect of raclopride and potentiates D2-blockage-induced dopamine release in the medial prefrontal cortex of the rat. Neuropsychopharmacology. 2002;27(5):691-698. (Pubitemid 35335887)
25. Marcus MM, Jardemark K, Malmerfelt A, Björkholm C, Svensson TH. Reboxetine enhances the olanzapine-induced antipsychotic-like effect, cortical dopamine outflow and NMD Areceptor-mediated transmission. Neuropsychopharmacology. 2010;35(9):1952-1961.
26. Joffe G, Terevnikov V, Joffe M, Stenberg JH, Burkin M, Tiihonen J. Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial. Schizophr Res. 2009;108(1-3):245-251.
27. Singh SP, Singh V, Kar N, Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry. 2010;197(3):174-179.
28. Haukka J, Tiihonen J, Härkänen T, Lönnqvist J. Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia. Pharmacoepidemiol Drug Saf. 2008;17(7):686-696.
29. Gardner DL, Cowdry RW. Alprazolam-induced dyscontrol in borderline personality disorder. Am J Psychiatry. 1985;142(1):98-100. (Pubitemid 15189529)
30. Charlson F, Degenhardt L, McLaren J, Hall W, Lynskey M. A systematic review of research examining benzodiazepine-related mortality. Pharmacoepidemiol Drug Saf. 2009;18(2):93-103.
31. Hausken AM, Skurtveit S, Tverdal A. Use of anxiolytic or hypnotic drugs and total mortality in a general middle-aged population. Pharmacoepidemiol Drug Saf. 2007;16(8):913-918. (Pubitemid 47333543)
32. Kripke DF, Simons RN, Garfinkel L, Hammond EC. Short and long sleep and sleeping pills: is increased mortality associated? Arch Gen Psychiatry. 1979;36(1):103-116. (Pubitemid 10187555)
33. Clark RE, Xie H, Brunette MF. Benzodiazepine prescription practices and substance abuse in persons with severe mental illness. J Clin Psychiatry. 2004;65(2):151-155.
34. Brunette MF, Noordsy DL, Xie H, Drake RE. Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders. Psychiatr Serv. 2003;54(10):1395-1401. (Pubitemid 37220041)